These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8852494)

  • 41. Reference ranges for serum C4 concentrations in subjects with and without C4 null alleles.
    Uko G; Christiansen FT; Dawkins RL; McCann VJ
    J Clin Pathol; 1986 May; 39(5):573-6. PubMed ID: 3722409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Statement on the nomenclature of dog C4 allotypes.
    Doxiadis G; Schoen W; Doxiadis I; Deeg HJ; O'Neill GJ; Grosse-Wilde H
    Immunogenetics; 1987; 25(3):167-70. PubMed ID: 3557563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of DNA amplification (PCR) and direct DNA sequencing in the characterization of C4 alleles.
    Berg ES; Markussen G; Teisberg P; Olaisen B
    Ann Hum Genet; 1990 Jul; 54(3):183-9. PubMed ID: 2221823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. C4 allotyping on plasma or serum: application to routine laboratories.
    Zhang WJ; Kay PH; Cobain TJ; Dawkins RL
    Hum Immunol; 1988 Mar; 21(3):165-71. PubMed ID: 3131277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new antigenic determinant for C4 of relatively low frequency.
    Giles CM; Jones JW
    Immunogenetics; 1987; 26(6):392-4. PubMed ID: 2444535
    [No Abstract]   [Full Text] [Related]  

  • 46. Phenotypes of the heavy chains of immunoglobulins in patients with diabetic microangiopathy: evidence for an immunogenetic predisposition.
    Mijovic C; Fletcher JA; Bradwell AR; Barnett AH
    Br Med J (Clin Res Ed); 1986 Feb; 292(6518):433-5. PubMed ID: 3081112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Usefulness of densitometry in typing of human complement component C4.
    Kramer J; Gyódi E; Füst G
    Immunogenetics; 1989; 29(2):121-3. PubMed ID: 2464544
    [No Abstract]   [Full Text] [Related]  

  • 48. Low C4 concentrations in insulin dependent diabetes mellitus.
    Dawkins RL; Uko G; Christiansen FT; Kay PH
    Br Med J (Clin Res Ed); 1983 Sep; 287(6395):839. PubMed ID: 6412852
    [No Abstract]   [Full Text] [Related]  

  • 49. Complement C4 phenotypes in dementia of the Alzheimer type.
    Eikelenboom P; Goetz J; Pronk JC; Hauptmann G
    Hum Hered; 1988; 38(1):48-51. PubMed ID: 3350531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. C4: another marker for type I diabetes.
    Bertrams J; Hintzen U; Schlicht V; Schoeps S
    Lancet; 1982 Jan; 1(8262):41. PubMed ID: 6119428
    [No Abstract]   [Full Text] [Related]  

  • 51. Low serum C4 concentrations in insulin dependent diabetes mellitus.
    Uko G; Christiansen FT; Dawkins RL; Kay PH
    Br Med J (Clin Res Ed); 1983 May; 286(6379):1748-9. PubMed ID: 6405964
    [No Abstract]   [Full Text] [Related]  

  • 52. Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.
    Freiwald T; Afzali B
    Adv Immunol; 2021; 152():1-81. PubMed ID: 34844708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study.
    Kalim S; Berg AH; Karumanchi SA; Thadhani R; Allegretti AS; Nigwekar S; Zhao S; Srivastava A; Raj D; Deo R; Frydrych A; Chen J; Sondheimer J; Shafi T; Weir M; Lash JP;
    Nephrol Dial Transplant; 2021 Dec; 37(1):139-147. PubMed ID: 33661286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.
    Kalim S; Tamez H; Wenger J; Ankers E; Trottier CA; Deferio JJ; Berg AH; Karumanchi SA; Thadhani RI
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1927-34. PubMed ID: 23970130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. C4 uremic variant: an acquired C4 allotype.
    Welch TR; Beischel L
    Immunogenetics; 1985; 22(6):553-62. PubMed ID: 3865892
    [TBL] [Abstract][Full Text] [Related]  

  • 56. C4 and Bf phenotypes in black and Caucasian patients with childhood onset insulin dependent diabetes mellitus.
    Wang C; Rivas ML; Burghen GA; Hudson EC; Wyatt RJ
    J Clin Lab Immunol; 1989 Dec; 30(4):183-90. PubMed ID: 2642174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymorphism of complement C4 and susceptibility to IDDM and microvascular complications.
    Lhotta K; Auinger M; Kronenberg F; Irsigler K; König P
    Diabetes Care; 1996 Jan; 19(1):53-5. PubMed ID: 8720534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polymorphism of the human complement component C4.
    Campbell RD; Dunham I; Kendall E; Sargent CA
    Exp Clin Immunogenet; 1990; 7(1):69-84. PubMed ID: 1971760
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Complement C4 phenotypes in patients with end-stage renal disease.
    Lhotta K; Schlögl A; Uring-Lambert B; Kronenberg F; König P
    Nephron; 1996; 72(3):442-6. PubMed ID: 8852494
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.